11:23:04 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-28 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-22 Kvartalsrapport 2024-Q1
2024-04-25 X-dag ordinarie utdelning SCOL 0.00 SEK
2024-04-24 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-04-27 X-dag ordinarie utdelning SCOL 0.00 SEK
2023-04-26 Årsstämma 2023
2023-02-22 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Kvartalsrapport 2022-Q1
2022-04-28 X-dag ordinarie utdelning SCOL 0.00 SEK
2022-04-27 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-11-17 Extra Bolagsstämma 2021
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 X-dag ordinarie utdelning SCOL 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-28 X-dag ordinarie utdelning SCOL 0.00 SEK
2020-05-27 Årsstämma 2020
2020-05-21 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-06-11 Extra Bolagsstämma 2019
2019-05-31 X-dag ordinarie utdelning SCOL 0.00 SEK
2019-05-29 Årsstämma 2019
2019-05-27 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018
2018-11-18 Kvartalsrapport 2018-Q3

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Scandion Oncology är verksamt inom bioteknik. Bolaget är fokuserat inom utveckling av läkemedel för behandling av cancer som innehåller läkemedelsresistenta cellkloner. Bolagets läkemedelskandidat, SCO-101, har i prekliniska studier använts inom olika standardcancerbehandlingar. Bolaget grundades under 2017 och har sitt huvudkontor i Köpenhamn, Danmark.
2023-08-17 08:30:00

Safety data from the PANTAX trial, studying SCO-101 in pancreatic cancer, has been accepted for poster presentation.

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will have clinical safety data for its lead compound SCO-101 presented at the European Society for Medical Oncology (ESMO) Congress 2023 taking place in Madrid on October 20-24, 2023. This will be a good opportunity for Scandion to make the safety data available to a large number of international physicians and other stakeholders.

Safety data from the PANTAX phase 1b trial in patients with pancreatic cancer will be announced at a poster presentation at the congress. This data will provide details to the topline results communicated in March 2023.

The primary endpoint of the PANTAX trial was achieved as the maximum tolerated dose of SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer was established at 200 milligrams given for 6 consecutive days every 2 weeks.

Scandion expects to perform a full analysis of all safety and efficacy outcomes late in 2023 with the final data to be presented in H1 2024.

For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com

The information was provided by the contact person above for publication on August 17, 2023, at 08.30 CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.